Cookies on GOV.UK

We use some essential cookies to make this website work.

We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.

We also use cookies set by other sites to help us deliver content from their services.

You have accepted additional cookies. You can change your cookie settings at any time.

You have rejected additional cookies. You can change your cookie settings at any time.

View cookies

Benefits
Births, death, marriages and care
Business and self-employed
Childcare and parenting
Citizenship and living in the UK
Crime, justice and the law
Disabled people
Driving and transport
Education and learning
Employing people
Environment and countryside
Housing and local services
Money and tax
Passports, travel and living abroad
Visas and immigration
Working, jobs and pensions

Government activity

Departments
Departments, agencies and public bodies
News
News stories, speeches, letters and notices
Guidance and regulation
Detailed guidance, regulations and rules
Research and statistics
Reports, analysis and official statistics
Policy papers and consultations
Consultations and strategy
Transparency
Data, Freedom of Information releases and corporate reports

Search GOV.UK

Search

Search GOV.UK

Home
Health and social care
Medicines, medical devices
Vigilance, safety alerts and guidance
Alerts and recalls

Drug Safety Update

From:: Medicines and Healthcare products Regulatory Agency

Alerts, recalls and safety information: medicines and medical devices

Search Drug Safety Update

Skip to results

Filter

163 updates

Therapeutic area

Anaesthesia and intensive care

Breastfeeding

Cancer

Cardiovascular disease and lipidology

Care home staff

Cosmetic surgery

Critical care

Dentistry

Dermatology

Dispensing GP practices

Ear, nose and throat

Emergency medicine

Endocrinology, diabetology and metabolism

General practice

General surgery

GI, hepatology and pancreatic disorders

Haematology and oncology

Immunology and vaccination

Immunosuppression and transplantation

Infection prevention

Infectious disease

Neurology

Nutrition and dietetics

Obstetrics, gynaecology and fertility

Ophthalmology

Orthopaedics

Paediatrics and neonatology

Pain management and palliation

Pathology

Pharmacy

Physiotherapy and occupational therapy

Pregnancy

Psychiatry

Radiology and imaging

Renal medicine

Respiratory disease and allergy

Rheumatology

Theatre practitioners

Urology and nephrology

Vascular and cardiac surgery

Published

Published after

For example, 2005 or 21/11/2014

Published before

For example, 2005 or 21/11/2014

163 updates

About Neurology

Go to search results

163 updates

Skip to results

Get emails
Subscribe to feed

163 updates

About Neurology

Phenytoin: risk of Stevens-Johnson syndrome associated with HLA-B*1502 allele in patients of Thai or Han Chinese ethnic origin

If patients are known to be HLA-B*1502-positive, phenytoinshould be avoided when alternative therapy can be given.
- Therapeutic area: Neurology
- Published: 11 December 2014
Vigabatrin for infantile spasms: risk of movement disorders and MRI abnormalities

If new movement disorders occur during treatment consider dose reduction or a gradual discontinuation of treatment in consultation with specialist advice.
- Therapeutic area: Neurology and 1 others
- Published: 11 December 2014
Rotigotine patches: lifting of prescribing restrictions

Cold-chain storage and distribution system now been fully implemented by manufacturer.
- Therapeutic area: Neurology
- Published: 11 December 2014
Antiepileptics: adverse effects on bone

Data suggests that long-term use of carbamazepine, phenytoin, primidone, and sodium valproate is associated with decreased bone mineral density that may lead to osteopenia, osteoporosis, and increased fractures.
- Therapeutic area: Neurology
- Published: 11 December 2014
Info on progressive multifocal leukoencephalopathy (PML) from Yellow Card reports

Spontaneous reporting on the Yellow Card portal has provided important information in the identification of PML associated with some drugs.
- Therapeutic area: Cancer and 3 others
- Published: 11 December 2014
Ergot-derived dopamine agonists: risk of fibrotic reactions

New warnings and contraindications for ergot-derived dopamine agonists due to risk of fibrosis associated with chronic use.
- Therapeutic area: Endocrinology, diabetology and metabolism and 1 others
- Published: 11 December 2014
Antiepileptics: risk of suicidal thoughts and behaviour

Antiepileptic treatment is associated with a small risk of suicidal thoughts and behaviour.
- Therapeutic area: Neurology
- Published: 11 December 2014
Ergot-derived dopamine agonists: risk of fibrosis

Do not prescribe ergots to patients who have had fibrosis in the heart, lungs, or abdomen.
- Therapeutic area: Endocrinology, diabetology and metabolism and 1 others
- Published: 11 December 2014
Telbivudine and pegylated interferon: risk of peripheral neuropathy

Patients who take telbivudine and pegylated interferon are at increased risk of peripheral neuropathy and should stop taking both medicines if symptoms occur.
- Therapeutic area: GI, hepatology and pancreatic disorders and 2 others
- Published: 11 December 2014
Herbal ingredient St John’s wort may interact with antiepileptics

Patients with epilepsy should not take products that contain St John’s wort as any antiepileptic medicine may interact with St John’s wort.
- Therapeutic area: Neurology
- Published: 11 December 2014
Ecoflac infusion solutions: risk of air embolism

To avoid the risk of air embolism, these products should not be infused under pressure.
- Therapeutic area: Anaesthesia and intensive care and 22 others
- Published: 11 December 2014
Botulinum toxin products: rare but serious risks

Products that contain botulinum toxin are associated with the risk of serious adverse reactions due to distant spread of toxin.
- Therapeutic area: Neurology and 1 others
- Published: 11 December 2014
Dopamine agonists: pathological gambling, increased libido, and hypersexuality

Healthcare professionals should warn patients that compulsive behaviour with dopamine agonists may be dose-related.
- Therapeutic area: Endocrinology, diabetology and metabolism and 1 others
- Published: 11 December 2014

Previous page:3 of 4

Get emails
Subscribe to feed

Is this page useful?

Thank you for your feedback

Help us improve GOV.UK

Do not include personal or financial information like your National Insurance number or credit card details.

This field is for robots only. Please leave blank

What were you doing?

What went wrong?

Help us improve GOV.UK

To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).

Services and information

Benefits
Births, death, marriages and care
Business and self-employed
Childcare and parenting
Citizenship and living in the UK
Crime, justice and the law
Disabled people
Driving and transport
Education and learning
Employing people
Environment and countryside
Housing and local services
Money and tax
Passports, travel and living abroad
Visas and immigration
Working, jobs and pensions

Government activity

Departments
News
Guidance and regulation
Research and statistics
Policy papers and consultations
Transparency
How government works
Get involved

All content is available under the Open Government Licence v3.0, except where otherwise stated